The Global Digital Biomarkers Market was valued at USD 4.8 billion in 2025 and is estimated to grow at a CAGR of 29.2% to reach USD 60.6 billion by 2035.
Market growth is fueled by advancements in sensor technologies, rising adoption of remote patient monitoring solutions, and the growing integration of AI-powered analytics into clinical research and healthcare delivery. The digital biomarkers market is gaining significant momentum as technology providers, pharmaceutical companies, and research organizations intensify investments in next-generation health monitoring tools. These stakeholders are advancing research and development efforts to introduce reliable and validated digital endpoints that enhance clinical trial efficiency and improve patient outcomes. Digital biomarkers refer to physiological, behavioral, and environmental data captured through connected devices such as wearables and sensor-enabled platforms. These data points enable continuous health assessment, disease progression tracking, and treatment evaluation. Increasing emphasis on precision medicine and personalized healthcare is further strengthening the adoption of digital biomarkers, positioning the global digital biomarkers market as a transformative force in modern healthcare systems.
The digital biomarkers market is advancing rapidly as organizations prioritize innovation and expand capabilities in data-centric healthcare technologies. Increased investment in research initiatives is driving the development of highly accurate and validated digital measurement tools. Continuous progress in analytical capabilities is enabling improved interpretation of complex health data, supporting more effective clinical decision-making and patient monitoring. The ability to generate actionable insights from continuous data streams is enhancing both research outcomes and healthcare delivery efficiency.
The wearable segment accounted for 42.5% share in 2025, making it the leading category. Wearable devices enable continuous tracking of key physiological and behavioral indicators, providing a more comprehensive data set compared to periodic clinical assessments. This constant monitoring supports early detection of health variations and allows timely medical intervention. In addition, wearables offer a more convenient and non-invasive approach to health monitoring, which increases user acceptance and encourages broader adoption. The combination of accessibility, comfort, and real-time data collection continues to drive growth within this segment.
The cardiovascular and metabolic disorders segment held a 22.6% share in 2025. This segment reflects the growing use of digital biomarkers in monitoring and managing chronic health conditions. Continuous tracking of physiological parameters enables healthcare providers to understand disease progression better and make informed treatment decisions. Advanced monitoring solutions support early identification of irregular health patterns, improving preventive care and long-term disease management. The increasing need for effective monitoring of chronic conditions is reinforcing demand within this segment.
North America Digital Biomarkers Market captured a notable share in 2025, supported by advanced healthcare infrastructure, widespread adoption of connected devices, and early implementation of AI-enabled analytics in clinical workflows. The region benefits from established regulatory frameworks that are increasingly supportive of digital health technologies and remote monitoring solutions. These regulatory advancements are accelerating the validation and adoption of digital biomarkers in both research and clinical environments. Additionally, the high prevalence of chronic conditions is driving demand for continuous and real-time health monitoring, further strengthening market growth across North America.
Key companies operating in the Global Digital Biomarkers Market include Ametris, AliveCor, Altoida, Amgen Inc., Adherium Limited, Aural Analytic, Brainomix, Biogen, Clario, Empatica Inc., Evidation Health Inc., IXICO plc, Koneksa, Sonde Health, Inc., and Vivo Sense. Companies in the Digital Biomarkers Market are adopting strategic initiatives to enhance their competitive position and expand their global footprint. A primary focus is placed on advancing research and development to create highly accurate, validated, and scalable digital health solutions. Organizations are increasingly integrating artificial intelligence and advanced analytics to improve data interpretation and clinical relevance. Strategic collaborations with healthcare providers, research institutions, and technology firms are enabling faster innovation and broader adoption. Companies are also investing in regulatory compliance and validation processes to strengthen credibility and accelerate market entry. Expanding product portfolios and enhancing platform capabilities are helping businesses address diverse healthcare needs. Additionally, improving user experience through intuitive interfaces and seamless device integration supports higher adoption rates and long-term customer engagement.
This product will be delivered within 2-4 business days.
Market growth is fueled by advancements in sensor technologies, rising adoption of remote patient monitoring solutions, and the growing integration of AI-powered analytics into clinical research and healthcare delivery. The digital biomarkers market is gaining significant momentum as technology providers, pharmaceutical companies, and research organizations intensify investments in next-generation health monitoring tools. These stakeholders are advancing research and development efforts to introduce reliable and validated digital endpoints that enhance clinical trial efficiency and improve patient outcomes. Digital biomarkers refer to physiological, behavioral, and environmental data captured through connected devices such as wearables and sensor-enabled platforms. These data points enable continuous health assessment, disease progression tracking, and treatment evaluation. Increasing emphasis on precision medicine and personalized healthcare is further strengthening the adoption of digital biomarkers, positioning the global digital biomarkers market as a transformative force in modern healthcare systems.
The digital biomarkers market is advancing rapidly as organizations prioritize innovation and expand capabilities in data-centric healthcare technologies. Increased investment in research initiatives is driving the development of highly accurate and validated digital measurement tools. Continuous progress in analytical capabilities is enabling improved interpretation of complex health data, supporting more effective clinical decision-making and patient monitoring. The ability to generate actionable insights from continuous data streams is enhancing both research outcomes and healthcare delivery efficiency.
The wearable segment accounted for 42.5% share in 2025, making it the leading category. Wearable devices enable continuous tracking of key physiological and behavioral indicators, providing a more comprehensive data set compared to periodic clinical assessments. This constant monitoring supports early detection of health variations and allows timely medical intervention. In addition, wearables offer a more convenient and non-invasive approach to health monitoring, which increases user acceptance and encourages broader adoption. The combination of accessibility, comfort, and real-time data collection continues to drive growth within this segment.
The cardiovascular and metabolic disorders segment held a 22.6% share in 2025. This segment reflects the growing use of digital biomarkers in monitoring and managing chronic health conditions. Continuous tracking of physiological parameters enables healthcare providers to understand disease progression better and make informed treatment decisions. Advanced monitoring solutions support early identification of irregular health patterns, improving preventive care and long-term disease management. The increasing need for effective monitoring of chronic conditions is reinforcing demand within this segment.
North America Digital Biomarkers Market captured a notable share in 2025, supported by advanced healthcare infrastructure, widespread adoption of connected devices, and early implementation of AI-enabled analytics in clinical workflows. The region benefits from established regulatory frameworks that are increasingly supportive of digital health technologies and remote monitoring solutions. These regulatory advancements are accelerating the validation and adoption of digital biomarkers in both research and clinical environments. Additionally, the high prevalence of chronic conditions is driving demand for continuous and real-time health monitoring, further strengthening market growth across North America.
Key companies operating in the Global Digital Biomarkers Market include Ametris, AliveCor, Altoida, Amgen Inc., Adherium Limited, Aural Analytic, Brainomix, Biogen, Clario, Empatica Inc., Evidation Health Inc., IXICO plc, Koneksa, Sonde Health, Inc., and Vivo Sense. Companies in the Digital Biomarkers Market are adopting strategic initiatives to enhance their competitive position and expand their global footprint. A primary focus is placed on advancing research and development to create highly accurate, validated, and scalable digital health solutions. Organizations are increasingly integrating artificial intelligence and advanced analytics to improve data interpretation and clinical relevance. Strategic collaborations with healthcare providers, research institutions, and technology firms are enabling faster innovation and broader adoption. Companies are also investing in regulatory compliance and validation processes to strengthen credibility and accelerate market entry. Expanding product portfolios and enhancing platform capabilities are helping businesses address diverse healthcare needs. Additionally, improving user experience through intuitive interfaces and seamless device integration supports higher adoption rates and long-term customer engagement.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Research Methodology
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2025
Chapter 5 Market Estimates and Forecast, by Type, 2022-2035 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Clinical Practice, 2022-2035 ($ Mn)
Chapter 7 Market Estimates and Forecast, by Therapeutic Area, 2022-2035 ($ Mn)
Chapter 8 Market Estimates and Forecast, by End Use, 2022-2035 ($ Mn)
Chapter 9 Market Estimates and Forecast, by Region, 2022-2035 ($ Mn)
Chapter 10 Company Profiles
Companies Mentioned
The companies profiled in this Digital Biomarkers market report include:- Ametris
- AliveCor
- Altoida
- Amgen Inc.
- Adherium Limited
- Aural Analytic
- Brainomix
- Biogen
- Clario
- Empatica Inc.
- Evidation Health Inc.
- IXICO plc
- Koneksa
- Sonde Health, Inc.
- Vivo Sense
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 120 |
| Published | April 2026 |
| Forecast Period | 2025 - 2035 |
| Estimated Market Value ( USD | $ 4.8 Billion |
| Forecasted Market Value ( USD | $ 60.6 Billion |
| Compound Annual Growth Rate | 29.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 16 |
